Skip to main content

Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting

Written by Petra Hegmann on . Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]